Pfizer stops commercialization of hemophilia gene therapy Beqvez
Pfizer has decided to stop global development and commercialization of its hemophilia gene therapy, Beqvez, due to soft demand from patients and their doctors. This decision was made after limited interest in gene therapies for the bleeding disorder, which is attributed to high costs, logistical issues, and potential treatment advances holding back adoption. The company will instead redirect resources towards Hympavzi, an injectable drug approved earlier this year.
- The halt of Beqvez's commercialization highlights the ongoing challenges in bringing innovative gene therapies to market, particularly for rare diseases with limited patient pools.
- What role should regulatory bodies play in mitigating the high costs and logistical barriers that prevent patients from accessing cutting-edge treatments like Beqvez?